Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Vaccines
Research on DNA vaccines detailed by H. Garren and co-authors
July 2nd, 2008
In this recent article published in the journal Annals of Neurology, scientists in the United States conducted a study "To evaluate the efficacy and safety of BHT-3009 in relapsing-remitting multiple sclerosis (MS) and to confirm that BHT-3009 causes immune tolerance. BHT-3009 is a tolerizing DNA vaccine for MS, encoding full-length human myelin basic protein." "Relapsing-remitting MS patients were randomized 1:1:1 into three groups: placebo, 0.5mg BHT-3009, or 1.5mg BHT-3009, given intramuscularly at weeks 0, 2, 4, and every 4 weeks thereafter until week 44. The primary end point was the 4-week rate of occurrence of new gadolinium-enhancing lesions on brain...
Source: Vaccine Weekly (2008-07-02)
|
